Nuo Therapeutics, Inc.
AURX
$1.52
-$0.02-1.30%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 106.48% | 100.46% | 59.78% | 208.63% | 283.96% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 106.48% | 100.46% | 59.78% | 208.63% | 283.96% |
| Cost of Revenue | 139.13% | 108.70% | 86.80% | 218.54% | 386.54% |
| Gross Profit | 97.50% | 98.26% | 51.57% | 206.45% | 262.92% |
| SG&A Expenses | 24.10% | 16.08% | -12.42% | -13.18% | -1.40% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 30.27% | 20.61% | -7.19% | -8.37% | 3.00% |
| Operating Income | -5.06% | 3.51% | 26.87% | 37.80% | 17.07% |
| Income Before Tax | -5.26% | 23.96% | 26.87% | 38.05% | 17.18% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -5.26% | 23.96% | 26.87% | 38.05% | 17.18% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.26% | 23.96% | 26.87% | 38.05% | 17.18% |
| EBIT | -5.06% | 3.51% | 26.87% | 37.80% | 17.07% |
| EBITDA | -3.44% | 4.72% | 27.04% | 37.97% | 17.11% |
| EPS Basic | 0.63% | 31.37% | 32.45% | 42.11% | 21.95% |
| Normalized Basic EPS | 0.00% | 12.50% | 32.48% | 41.54% | 21.88% |
| EPS Diluted | 0.63% | 31.37% | 32.45% | 42.11% | 21.95% |
| Normalized Diluted EPS | 0.00% | 12.50% | 32.48% | 41.54% | 21.88% |
| Average Basic Shares Outstanding | 5.82% | 10.83% | 8.24% | 6.84% | 5.84% |
| Average Diluted Shares Outstanding | 5.82% | 10.83% | 8.24% | 6.84% | 5.84% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |